×
验证码:
换一张
Forgotten Password?
Stay signed in
Login With UMPASS
English
|
繁體
Login With UMPASS
Log In
ALL
ORCID
TI
AU
PY
SU
KW
TY
JN
DA
IN
PB
FP
ST
SM
Study Hall
Image search
Paste the image URL
Home
Faculties & Institutes
Scholars
Publications
Subjects
Statistics
News
Search in the results
Faculties & Institutes
Institute of Chi... [9]
Faculty of Healt... [7]
THE STATE KEY LA... [7]
Authors
LU JINJIAN [9]
CHEN XIUPING [5]
WANG YITAO [1]
Document Type
Journal article [8]
Review article [1]
Date Issued
2023 [3]
2022 [1]
2021 [3]
2020 [2]
Language
英語English [8]
Source Publication
Acta Pharmaceuti... [2]
Translational On... [2]
Acta Pharmacolog... [1]
Drug Discovery T... [1]
Frontiers of Med... [1]
Pharmacological ... [1]
More...
Indexed By
SCIE [8]
Funding Organization
Funding Project
×
Knowledge Map
UM
Start a Submission
Submissions
Unclaimed
Claimed
Attach Fulltext
Bookmarks
Browse/Search Results:
1-9 of 9
Help
Selected(
0
)
Clear
Items/Page:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Sort:
Select
Issue Date Ascending
Issue Date Descending
Journal Impact Factor Ascending
Journal Impact Factor Descending
WOS Cited Times Ascending
WOS Cited Times Descending
Submit date Ascending
Submit date Descending
Title Ascending
Title Descending
Author Ascending
Author Descending
Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10
Journal article
Huang, Mu Yang, Chen, Yu Chi, Lyu, Wen Yu, He, Xin Yu, Ye, Zi Han, Huang, Can Yu, He, Xin Ling, Chen, Xiuping, Chen, Xiaobing, Zhang, Baoxian, Kai, Guoyin, Zhang, Xiaolei, Li, Ting, Huang, Mingqing, Lu, Jin Jian. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10[J]. Pharmacological Research, 2023, 198, 106988.
Authors:
Huang, Mu Yang
;
Chen, Yu Chi
;
Lyu, Wen Yu
;
He, Xin Yu
;
Ye, Zi Han
; et al.
Favorite
|
TC[WOS]:
11
TC[Scopus]:
14
IF:
9.1
/
9.0
|
Submit date:2024/01/02
Combination Treatment
Ginsenoside Rh2
Pd-1/pd-l1
t Cells
Tumor Microenvironment
Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives
Review article
2023
Authors:
Ye, Zi Han
;
Yu, Wei Bang
;
Huang, Mu Yang
;
Chen, Jun
;
Lu, Jin Jian
Favorite
|
TC[WOS]:
9
TC[Scopus]:
10
IF:
14.7
/
14.1
|
Submit date:2023/05/02
Bispecific Antibodies
Cancer
Cd47
Clinical Data
Combination Strategies
Future Perspectives
Mechanisms
Preclinical Data
Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives
Journal article
Ye,Zi Han, Yu,Wei Bang, Huang,Mu Yang, Chen,Jun, Lu,Jin Jian. Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives[J]. Acta Pharmaceutica Sinica B, 2023, 13(4), 1467-1487.
Authors:
Ye,Zi Han
;
Yu,Wei Bang
;
Huang,Mu Yang
;
Chen,Jun
;
Lu,Jin Jian
Favorite
|
TC[WOS]:
9
TC[Scopus]:
10
IF:
14.7
/
14.1
|
Submit date:2023/08/03
Bispecific Antibodies
Cancer
Cd47
Clinical Data
Combination Strategies
Future Perspectives
Mechanisms
Preclinical Data
CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer
Journal article
Wei-Bang Yu, Yu-Chi Chen,, Can-Yu Huang, Zi-Han Ye, Wei Shi, Hong Zhu, Jia-Jie Shi, Jun Chen, Jin-Jian Lu. CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer[J]. Frontiers of Medicine, 2022, 17(1), 105-118.
Authors:
Wei-Bang Yu
;
Yu-Chi Chen,
;
Can-Yu Huang
;
Zi-Han Ye
;
Wei Shi
; et al.
Favorite
|
TC[WOS]:
2
TC[Scopus]:
2
IF:
3.9
/
5.4
|
Submit date:2023/01/30
Adcp
Anti-cd47 Antibody
Combination Strategy
Egfr
Osimertinib
Regulation of CD47 expression by interferon-gamma in cancer cells
Journal article
Ye, Zi Han, Jiang, Xiao Ming, Huang, Mu Yang, Xu, Yu Lian, Chen, Yu Chi, Yuan, Luo Wei, Huang, Can Yu, Yu, Wei Bang, Chen, Xiuping, Lu, Jin Jian. Regulation of CD47 expression by interferon-gamma in cancer cells[J]. Translational Oncology, 2021, 14(9), 101162.
Authors:
Ye, Zi Han
;
Jiang, Xiao Ming
;
Huang, Mu Yang
;
Xu, Yu Lian
;
Chen, Yu Chi
; et al.
Favorite
|
TC[WOS]:
15
TC[Scopus]:
19
IF:
4.5
/
4.2
|
Submit date:2021/12/08
The development of small-molecule inhibitors targeting CD47
Journal article
Yu,Wei Bang, Ye,Zi Han, Chen,Xiuping, Shi,Jia Jie, Lu,Jin Jian. The development of small-molecule inhibitors targeting CD47[J]. Drug Discovery Today, 2021, 26(2), 561-568.
Authors:
Yu,Wei Bang
;
Ye,Zi Han
;
Chen,Xiuping
;
Shi,Jia Jie
;
Lu,Jin Jian
Favorite
|
TC[WOS]:
47
TC[Scopus]:
48
IF:
6.5
/
7.3
|
Submit date:2021/03/01
Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells
Journal article
Yuan,Luo Wei, Jiang,Xiao Ming, Xu,Yu Lian, Huang,Mu Yang, Chen,Yu Chi, Yu,Wei Bang, Su,Min Xia, Ye,Zi Han, Chen,Xiuping, Wang,Yitao, Lu,Jin Jian. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells[J]. Phytomedicine, 2021, 80(153394).
Authors:
Yuan,Luo Wei
;
Jiang,Xiao Ming
;
Xu,Yu Lian
;
Huang,Mu Yang
;
Chen,Yu Chi
; et al.
Favorite
|
TC[WOS]:
33
TC[Scopus]:
36
IF:
6.7
/
6.2
|
Submit date:2021/03/01
Pd-l1
Ifn-γ
Natural Products
Licochalcone a
Protein Synthesis Inhibitor
Ros
Regulation of CD47 expression in cancer cells
Journal article
Huang,Can Yu, Ye,Zi Han, Huang,Mu Yang, Lu,Jin Jian. Regulation of CD47 expression in cancer cells[J]. Translational Oncology, 2020, 13(12), 100862.
Authors:
Huang,Can Yu
;
Ye,Zi Han
;
Huang,Mu Yang
;
Lu,Jin Jian
Favorite
|
TC[WOS]:
55
TC[Scopus]:
61
IF:
4.5
/
4.2
|
Submit date:2021/03/02
Cd47
Cytokine
Microrna
Oncogene
Qpctl
TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance
Journal article
Jiang,Xiao ming, Xu,Yu lian, Yuan,Luo wei, Zhang,Le le, Huang,Mu yang, Ye,Zi han, Su,Min xia, Chen,Xiu ping, Zhu,Hong, Ye,Richard D., Lu,Jin jian. TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance[J]. Acta Pharmacologica Sinica, 2020, 42(3), 451-459.
Authors:
Jiang,Xiao ming
;
Xu,Yu lian
;
Yuan,Luo wei
;
Zhang,Le le
;
Huang,Mu yang
; et al.
Favorite
|
TC[WOS]:
40
TC[Scopus]:
39
IF:
6.9
/
7.6
|
Submit date:2021/03/01
Egfr Mutant Non-small Cell Lung Cancer
Emt
Nf-κb
Osimertinib Resistance
Tgfβ2